protocolSection identificationModule nctId: NCT06281106, orgStudyIdInfo id: IM011-1118, secondaryIdInfos id: KOFAM 2023-01731, type: OTHER, domain: CER-VD, briefTitle: TYK2 Inhibition in Paradoxical Psoriasis, acronym: TYPP, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-08, completionDateStruct date: 2025-08, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Prof Curdin Conrad, class: OTHER, collaborators name: Centre Hospitalier Universitaire Vaudois, descriptionModule briefSummary: Paradoxical psoriasis is a side effect of a biological treatment (anti-tumor necrosis factor agent, short called anti-TNF) that is used to treat diseases of the skin, the intestine or the joints. If paradoxical psoriasis occurs, the anti-TNF-treatment often needs to be stopped and so far, no specific treatment for paradoxical psoriasis exists.This research project aims to study whether the efficacy of the drug 'Deucravacitinib' 6mg, a tablet taken by mouth once a day is superior compared to taking a placebo in treating paradoxical psoriasis., conditionsModule conditions: Psoriasis, designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: During 4 weeks the patients of the 2 arms receive either Deucravacitinib 6mg 1x/day or an identically looking placebo.At Week 4, Patients with underlying disease of Crohn's disease, colitis ulcerosa, uveitis will stop the study, to avoid that they are too long without efficient treatment for their underlying disease.Patients with underlying disease of psoriasis or psoriatic arthritis will have the possiblity to continue in Part 2, where they all will receive Deucravacitinib 6mg 1x/day, open label for 3 months, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, maskingDescription: Lab personnel, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 26, type: ESTIMATED, armsInterventionsModule interventions name: Deucravacitinib, outcomesModule primaryOutcomes measure: Paradoxical Psoriasis Investigator Global Assessment, secondaryOutcomes measure: Paradoxical Psoriasis Body Surface Area, secondaryOutcomes measure: Paradoxical Psoriasis palmoplantar Psoriasis Area and Severity Index, secondaryOutcomes measure: Paradoxical Psoriasis Scalp Investigator General Assessment, secondaryOutcomes measure: Psoriasis Area and Severity Index (PASI), secondaryOutcomes measure: American College of Rheumatology (ACR) Score, otherOutcomes measure: Nanostring, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Centre hospitalier universitaire vaudois (CHUV), city: Lausanne, state: VD, zip: 1011, country: Switzerland, contacts name: Franziska Stuber, RN, role: CONTACT, phone: +41 21 3143427, email: franziska.stuber@chuv.ch, contacts name: Curdin Conrad, Professor, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 46.516, lon: 6.63282, hasResults: False